Hormone Therapy for Gynecologic Cancers

Introduction

If you have been diagnosed with a gynecologic cancer — a cancer of the uterus, ovaries, or related organs — your care team may have discussed hormone therapy as part of your treatment plan. Hormone therapy (also called hormonal therapy or endocrine therapy) is a type of medication treatment that works by changing the hormone signals that some cancers depend on to grow.

Hormone therapy is not used for every gynecologic cancer. It is used in carefully selected situations — most often for certain endometrial (uterine) cancers and a smaller group of ovarian cancers — where tests show that the tumour is likely to respond to changes in hormone levels. For these patients, it can be a meaningful option, sometimes used in place of chemotherapy and sometimes alongside or after other treatments.

This guide explains what hormone therapy is, how it works, which cancers it is used for, what the treatment plan looks like, what side effects to expect, and how response is monitored. It is written for patients who already have a diagnosis and are considering or starting this treatment. Specific decisions about whether hormone therapy is right for your situation belong in conversations with your gynecologic oncologist.

What Is Hormone Therapy for Gynecologic Cancers?

Hormone therapy is a cancer treatment that uses medications to block, lower, or change the effect of hormones in the body. Some cancers are described as hormone-sensitive or hormone-receptor-positive, which means that hormones such as estrogen or progesterone act like a fuel source that helps the cancer cells divide and grow.

By cutting off or interfering with this hormonal signal, hormone therapy can:

• Slow the growth of the cancer
• Shrink some tumours
• Delay the time before the disease progresses
• Reduce the chance of recurrence in selected situations

Hormone therapy is different from chemotherapy. Chemotherapy uses cytotoxic drugs that directly damage rapidly dividing cells, including cancer cells. Hormone therapy does not attack cells in the same way — instead, it changes the hormonal environment around the cancer. As a result, it is usually better tolerated than chemotherapy, although it has its own set of side effects.

The term “hormone therapy” in cancer care is the opposite of hormone replacement therapy used for menopause. In cancer treatment, the goal is generally to reduce hormone activity, not replace it.

How Hormone Therapy Works

Cells in some tissues, including the lining of the uterus and certain ovarian tissues, carry hormone receptors — molecules on or inside the cell that bind to hormones such as estrogen and progesterone. When a hormone binds to its receptor, it sends a signal that can influence cell growth.

If a cancer arises from one of these tissues and keeps its hormone receptors, the tumour cells can use estrogen or progesterone signals to keep multiplying. A biopsy can be tested to see whether the tumour is estrogen receptor positive (ER+), progesterone receptor positive (PR+), or both. Cancers that are ER+ or PR+ are more likely to respond to hormone therapy.

Hormone therapy medications interrupt this signal in one of several ways:

• Adding progesterone-like signals that override estrogen’s growth-promoting effect on the endometrium
• Lowering estrogen production in the body so less estrogen reaches the cancer
• Blocking estrogen receptors so estrogen cannot attach to the cancer cell
• Switching off ovarian hormone production by acting on the brain’s signals to the ovaries

The right strategy depends on the type of cancer, its receptor status, whether you have reached menopause, your overall health, and any previous treatments you have had.

Which Gynecologic Cancers Is Hormone Therapy Used For?

Endometrial (Uterine) Cancer

Endometrial cancer begins in the lining of the uterus. The most common type, endometrioid endometrial cancer, is often driven by estrogen and frequently expresses estrogen and progesterone receptors. This makes it the gynecologic cancer most commonly treated with hormone therapy.

Hormone therapy may be considered in endometrial cancer in several situations:

• Advanced or recurrent disease — when surgery and radiation are not enough on their own, or when the cancer has come back, hormone therapy can be used to control disease, sometimes for long periods
• Patients who cannot tolerate chemotherapy because of age, frailty, or other health conditions
• Fertility-sparing treatment — in carefully selected young women with very early-stage, low-grade endometrial cancer or its precursor (atypical endometrial hyperplasia) who wish to preserve the option of pregnancy, hormone therapy (most often progestins, sometimes delivered via a hormone-releasing intrauterine device) can be used in place of immediate hysterectomy. This approach is described in NCCN and ESGO/ESTRO/ESP guidelines and requires close monitoring with repeated endometrial sampling
• Maintenance therapy after other treatments in some situations

Ovarian Cancer

Ovarian cancer covers several different tumour types, and only some are hormone-sensitive. Hormone therapy is most often considered for:

• Low-grade serous ovarian cancer — a slow-growing subtype that often expresses hormone receptors and may respond well to hormone-based treatment. Major guidelines including NCCN now recognise hormone therapy as a reasonable option in this subtype, including as maintenance after surgery
• Recurrent epithelial ovarian cancer — in some patients with hormone-receptor-positive disease where chemotherapy is not appropriate or has been used multiple times already
• Granulosa cell tumours and other rare sex cord-stromal tumours of the ovary, which can be hormone-responsive

Hormone therapy is generally not effective for high-grade serous ovarian cancer, which is the most common subtype, except in selected hormone-receptor-positive cases where other options are limited.

Other Situations

Hormone therapy is occasionally used for:

• Uterine sarcomas, particularly low-grade endometrial stromal sarcoma, which is often strongly hormone-responsive
• Recurrent cervical or vaginal cancers in rare hormone-receptor-positive situations

Progestins

Progestins are synthetic versions of the hormone progesterone. In hormone-sensitive endometrial cancer, progestins counteract the growth-stimulating effect of estrogen on the endometrium. Common progestins used include medroxyprogesterone acetate and megestrol acetate, usually taken as tablets.

In fertility-sparing treatment for early endometrial cancer, a levonorgestrel-releasing intrauterine system (a hormonal IUD) is sometimes used to deliver progestin directly to the uterine lining, alone or together with oral progestin.

Aromatase Inhibitors

Aromatase inhibitors lower the level of estrogen in the body by blocking the enzyme aromatase, which converts other hormones into estrogen in fat tissue, muscle, and elsewhere. They are most effective in postmenopausal women, because in younger women the ovaries can still produce estrogen by other pathways.

Drugs in this class include letrozole, anastrozole, and exemestane, taken as daily tablets. They are commonly used in low-grade serous ovarian cancer, in advanced or recurrent endometrial cancer, and in some uterine sarcomas.

Selective Estrogen Receptor Modulators (SERMs)

SERMs such as tamoxifen attach to estrogen receptors and block estrogen’s effects on cancer cells. Tamoxifen is sometimes used in gynecologic cancers, usually in combination or sequence with other hormone treatments.

GnRH Agonists

Gonadotropin-releasing hormone (GnRH) agonists, such as goserelin and leuprolide, are given by injection. They act on the brain’s signals to the ovaries and, after an initial brief rise, suppress ovarian hormone production. They are used in premenopausal patients with hormone-sensitive disease to put the ovaries into a temporary “switched off” state.

Newer Hormone-Based Combinations

Research has explored combinations of hormone therapy with targeted drugs that block growth pathways, such as everolimus (an mTOR inhibitor) added to letrozole in some endometrial cancers. These combinations are not standard for every patient but are options that gynecologic oncologists may consider in specific situations.

How Treatment Decisions Are Made

Whether hormone therapy is suitable in your case depends on several factors that your gynecologic oncologist considers together:

• Tumour type and grade — low-grade tumours tend to respond better than high-grade ones
• Hormone receptor status — tested on the tumour tissue from biopsy or surgery
• Stage and extent of disease
• Whether the cancer is newly diagnosed or recurrent
• Previous treatments received
• Your menopausal status and overall health
• Other medical conditions such as a history of blood clots, heart disease, or osteoporosis, which can affect drug choice
• Your priorities, including fertility preservation if relevant, and tolerance for side effects

Before starting, you can expect a pre-treatment evaluation that typically includes a review of your pathology report (including receptor testing), imaging to assess disease extent, blood tests, and a discussion of expected benefits, limitations, and side effects.

The Treatment Plan and What to Expect

Hormone therapy is usually given continuously over months or years, rather than in short cycles. Most patients take medication at home and visit the clinic for monitoring rather than for treatment delivery itself.

How Treatment Is Given

• Oral tablets, taken daily — the most common form for progestins, aromatase inhibitors, and SERMs
• Intramuscular or subcutaneous injections, usually monthly or every three months — for GnRH agonists
• Intrauterine device — for selected fertility-sparing endometrial cancer treatment, replaced periodically

How Long Treatment Lasts

There is no fixed duration. Common patterns include:

• Until the cancer progresses, in advanced or recurrent disease — this may be months or several years
• For a defined period in fertility-sparing endometrial cancer treatment, with response checked every 3 to 6 months by endometrial sampling; if the cancer responds completely, treatment may pause to allow attempts at pregnancy, with definitive surgery often recommended afterwards
• As maintenance after primary treatment in some low-grade serous ovarian cancer protocols, sometimes continuing for years

Daily Life on Hormone Therapy

Because hormone therapy is generally taken at home and does not cause the steep ups and downs of chemotherapy cycles, most patients can continue daily activities — work, travel, family life — with relatively little disruption. The most common challenges are managing menopause-like side effects and remembering to take medication consistently.

Side Effects and How They Are Managed

Common Side Effects

• Hot flashes and night sweats
• Fatigue
• Mood changes, including low mood and irritability
• Weight gain, particularly with progestins
• Vaginal dryness and reduced libido
• Joint and muscle aches, particularly with aromatase inhibitors
• Headaches
• Nausea, usually mild and often improving over weeks
• Breast tenderness or changes

Less Common but Important Side Effects

• Blood clots in the legs or lungs (deep vein thrombosis, pulmonary embolism) — risk is higher with some progestins and with tamoxifen; patients with a personal or family history of clots need careful evaluation
• Bone thinning (osteoporosis) with long-term use of aromatase inhibitors or GnRH agonists, which can increase fracture risk
• Changes in cholesterol or blood sugar
• Liver enzyme changes, usually mild and reversible
• Endometrial changes with tamoxifen, including a small increased risk of endometrial cancer in patients who still have a uterus (less relevant for many gynecologic cancer patients who have already had hysterectomy)
• Cardiovascular effects with some agents

How Side Effects Are Managed

Most side effects are manageable, and your care team will help you find approaches that fit your situation. Common strategies include:

• Lifestyle measures — layered clothing for hot flashes, regular gentle exercise for joint stiffness and mood, sleep hygiene for fatigue
• Bone health support — calcium, vitamin D, weight-bearing exercise, and periodic bone density scans, with bone-protective medications added when needed
• Vaginal moisturisers and non-hormonal lubricants for vaginal dryness; hormonal vaginal treatments are usually avoided in hormone-sensitive cancer but can sometimes be considered in selected cases after discussion with your oncologist
• Medications for specific symptoms, including non-hormonal options for hot flashes and mood support
• Dose adjustments or switching to a different drug in the same class if a particular agent is poorly tolerated
• Monitoring of cholesterol, blood pressure, and metabolic markers

It is important to tell your care team about new symptoms rather than waiting until they become severe. Calf swelling, sudden breathlessness, chest pain, severe headache, or unusual bleeding should be reported promptly.

Response and Monitoring

Because hormone therapy works gradually, response is assessed over weeks to months rather than days. Monitoring usually combines clinical review, imaging, and (depending on the cancer) tumour markers or repeat sampling.

How Response Is Measured

• Imaging studies — CT, MRI, or ultrasound, repeated every few months to compare tumour size and look for new lesions
• Blood tests for tumour markers — for example, CA-125 in ovarian cancer, used as a trend rather than a single number
• Endometrial biopsy or hysteroscopy — in fertility-sparing endometrial cancer treatment, repeated typically every 3 months to confirm the cancer is responding
• Symptom review — pain, bleeding, bloating, and other symptoms can give clues about how well treatment is controlling disease

Possible Outcomes

• Complete response — the cancer is no longer visible on imaging or sampling. This is more common in early endometrial cancer treated for fertility preservation than in advanced disease
• Partial response — the cancer has shrunk but is still present
• Stable disease — the cancer is not shrinking but is not growing either; this is considered a treatment success in many advanced cancers and can last for long periods
• Progression — the cancer grows or new lesions appear, in which case treatment is reviewed and changed

It is helpful to think of hormone therapy in advanced disease as a way of controlling cancer rather than curing it. For many patients, long periods of stable or shrinking disease with manageable side effects are a realistic and valuable goal. Personalised estimates of how likely you are to respond, and for how long, are best discussed with your gynecologic oncologist based on your specific tumour and situation.

Combining Hormone Therapy with Other Treatments

Hormone therapy can be used in several ways in relation to other cancer treatments:

• As primary treatment, particularly in fertility-sparing endometrial cancer protocols or when surgery and chemotherapy are not appropriate
• After surgery and/or radiation, to reduce the risk of recurrence in selected hormone-sensitive cancers
• For recurrent or metastatic disease, either alone or in sequence with chemotherapy
• As maintenance therapy — for example, after surgery for low-grade serous ovarian cancer to keep disease in check
• Alongside targeted therapy, such as aromatase inhibitors combined with mTOR inhibitors in some endometrial cancer protocols, or with CDK4/6 inhibitors in selected research-based situations

Hormone therapy is usually not given at the same time as cytotoxic chemotherapy, because the strategies can interfere with each other and side effects may overlap. Your oncologist will plan the sequencing carefully.

Fertility and Hormone Therapy

For young women diagnosed with very early-stage, low-grade endometrial cancer (or its precursor, atypical hyperplasia) who wish to preserve the option of having children, fertility-sparing hormone therapy may be considered as an alternative to immediate hysterectomy. This is a specialist decision based on strict criteria. Major guidelines, including those from NCCN and European societies, describe this option for carefully selected patients.

What this generally involves:

• Detailed imaging (often including MRI) to confirm the cancer is limited to the lining of the uterus, with no deep muscle invasion or spread
• Treatment with progestins (oral, intrauterine device, or both) for several months
• Repeat endometrial sampling every few months to check response
• If complete response is achieved, an opportunity to attempt pregnancy, often with fertility specialist support
• Definitive hysterectomy is usually recommended after childbearing is complete, because the risk of recurrence or further cancer in the uterus remains

This approach is not appropriate for all early endometrial cancers and is not used in higher-grade tumours or those with deeper invasion. A thorough discussion with a gynecologic oncologist, often together with a fertility specialist, is essential.

For other gynecologic cancers and other situations, hormone therapy is not generally a fertility-preserving treatment. Patients who hope to have children in the future should ask about fertility preservation options (such as egg or embryo freezing) before starting any cancer treatment, including hormone therapy.

Living During Hormone Therapy

Because hormone therapy often continues for many months or years, attention to general health and wellbeing becomes part of the treatment itself.

Bone Health

Aromatase inhibitors, GnRH agonists, and the menopausal state induced by treatment can all accelerate bone loss. Strategies that are commonly recommended include:

• Adequate dietary calcium and vitamin D
• Weight-bearing exercise such as walking
• Resistance and balance exercises to reduce falls
• Periodic bone density (DEXA) scans
• Bone-protective medications (bisphosphonates or others) when indicated
• Avoiding smoking and limiting alcohol

Heart and Metabolic Health

Hormonal changes can affect cholesterol, blood pressure, blood sugar, and body weight. Regular monitoring and attention to diet and activity can help reduce long-term cardiovascular risk.

Sexual Health and Intimacy

Vaginal dryness, reduced libido, and discomfort during sex are common but often unspoken. Non-hormonal vaginal moisturisers and lubricants can help. Pelvic floor physiotherapy and counselling are options that some patients find valuable. Open conversations with partners and with the care team make a real difference; nothing on this list needs to be tolerated in silence.

Emotional Wellbeing

A long course of treatment for cancer, alongside hormonal side effects, can affect mood, sleep, and sense of self. Many patients find support helpful, whether through counselling, peer support groups, or simply scheduled conversations with someone they trust. If you notice persistent low mood, anxiety, or difficulty coping, tell your care team — these are recognised parts of cancer treatment, not signs of weakness.

Day-to-Day Practical Tips

• Take medications at the same time each day to build a routine
• Keep a simple log of side effects to discuss at clinic visits
• Plan follow-up appointments well in advance, including imaging and blood tests
• Tell other doctors and dentists about your hormone therapy before they start new medications
• Carry a list of your current medications when travelling

When to Contact Your Care Team

Hormone therapy is generally less acutely dangerous than chemotherapy, but some symptoms still need prompt attention. Contact your care team if you notice:

• Swelling, pain, redness, or warmth in one leg — possible blood clot
• Sudden shortness of breath, chest pain, or coughing up blood — possible clot in the lung; seek emergency care
• Sudden severe headache, weakness on one side of the body, or vision change — seek emergency care
• New or worsening abdominal pain, bloating, or changes in bowel habits
• Unexpected vaginal bleeding
• Yellowing of skin or eyes, or persistent nausea and vomiting
• Severe mood changes or thoughts of self-harm
• Any new symptom that concerns you, even if it is not on this list

Long-Term Outlook

The long-term outlook on hormone therapy depends heavily on the type of cancer, its stage, and how it responds to treatment. Some general patterns:

• In fertility-sparing treatment for early endometrial cancer, many carefully selected patients achieve a complete response, and some are able to have children before completing definitive surgery later
• In advanced or recurrent endometrial cancer, hormone therapy can control disease for months to years in patients whose tumours are hormone-receptor-positive and lower grade
• In low-grade serous ovarian cancer, hormone therapy is increasingly used both as initial maintenance after surgery and for recurrent disease, with many patients having long periods of disease control
• In high-grade or hormone-receptor-negative cancers, hormone therapy is less effective and is not usually a primary treatment

Even when hormone therapy stops being effective, other treatments — including different hormone agents, chemotherapy, targeted therapy, immunotherapy, surgery, or radiation — may still be options. Cancer care is increasingly a sequence of treatments rather than a single decision, and hormone therapy is one important tool in that sequence.

Frequently Asked Questions

Is hormone therapy a type of chemotherapy?

No. Chemotherapy uses drugs that damage rapidly dividing cells throughout the body. Hormone therapy works by changing hormone levels or blocking hormone signals that some cancers rely on for growth. The two treatments work differently, have different side effects, and are sometimes used at different points in care.

Will hormone therapy cure my cancer?

This depends on the situation. In fertility-sparing treatment of very early endometrial cancer, hormone therapy can clear the cancer in selected patients, although definitive surgery is usually recommended later. In advanced or recurrent disease, hormone therapy more often controls cancer than cures it — sometimes for long periods. Your gynecologic oncologist can give you a more specific picture based on your tumour.

How will I know if hormone therapy is working?

Response is assessed through imaging, blood tests (such as tumour markers in ovarian cancer), endometrial sampling where relevant, and symptom review. Because hormone therapy works gradually, your team will usually wait some months before judging response, rather than expecting fast changes.

Do I need to stop hormone replacement therapy or birth control before starting?

Generally yes. Estrogen-based hormone replacement therapy and combined hormonal birth control can interfere with treatment of hormone-sensitive cancers and are usually stopped. Your care team will guide you on safe alternatives if symptoms such as hot flashes become difficult.

Can I take hormone therapy alongside other medications?

Most everyday medications can be taken alongside hormone therapy, but interactions are possible — for example, some drugs can affect liver enzymes that metabolise hormone treatments. Always tell each doctor, dentist, and pharmacist that you are on cancer hormone therapy, and check before starting new medications, including supplements and herbal products.

Will hormone therapy put me into menopause?

If you are still premenopausal, some hormone treatments (especially GnRH agonists, and the menopause-like state required for aromatase inhibitors to work well) will produce menopausal symptoms. Whether the effect on the ovaries is temporary or permanent depends on the drug, your age, and the duration of treatment. Discuss this with your oncologist, especially if fertility matters to you.

Can I work and travel during hormone therapy?

Most patients can continue normal activities, including work and travel. Fatigue and hot flashes can affect daily life and may need adjustment in routine. Long-haul travel may slightly increase clot risk on certain drugs — ask your care team about precautions such as compression stockings and movement during flights.

What happens if hormone therapy stops working?

If the cancer starts to progress, your oncologist will review options. Sometimes a different hormone agent works when another has stopped. Other options include chemotherapy, targeted therapy, immunotherapy, surgery for specific lesions, or radiation. Treatment plans are usually reviewed at a multidisciplinary tumour board.

Does hormone therapy increase the risk of other cancers?

Some hormone agents have small specific risks. Tamoxifen, for example, can slightly increase the risk of endometrial cancer in patients who still have a uterus. These risks are generally small compared with the benefit of treating the existing cancer, but they are factors your oncologist weighs when choosing a drug.

Conclusion

Hormone therapy is a focused, generally well-tolerated treatment option for selected gynecologic cancers, particularly hormone-receptor-positive endometrial and low-grade ovarian cancers. By interrupting the hormonal signals that fuel these tumours, it can shrink or stabilise disease, sometimes for long periods, and in carefully chosen early endometrial cancers it can support fertility preservation.

Like all cancer treatments, it has its own pattern of side effects and requires regular monitoring. Long-term care focuses not just on cancer control but on bone health, heart health, sexual wellbeing, and emotional support, because treatment may continue for many months or years.

Whether hormone therapy is appropriate for your specific cancer, and how it fits with other treatments you may need, is a decision that belongs in a detailed conversation with your gynecologic oncologist. Understanding what the treatment is, how it works, and what to expect can help you take part in that conversation with more confidence.